Also trades as: FRX.TO (TSX) · $vol 0M
FENC NASDAQ
Fennec Pharmaceuticals Inc.
1W: -12.7%
1M: -7.3%
3M: +23.8%
YTD: +42.7%
1Y: +21.6%
3Y: +37.7%
5Y: +36.1%
$10.96
-0.34 (-3.01%)
Weekly Expected Move ±6.4%
$10
$10
$11
$12
$12
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Smart Money Score
Moderate
50
Insider—
Congress—
ETF Holdings—
Key Statistics
Market Cap$380.7M
52W Range5.65-13.25
Volume249,926
Avg Volume267,503
Beta1.10
Dividend—
Analyst Ratings
Company Info
CEOJeffrey S. Hackman
Employees35
SectorHealthcare
IndustryBiotechnology
IPO Date2017-09-15
Websitefennecpharma.com
68 TW Alexander Drive
Research Triangle Park, NC 27709
US
Research Triangle Park, NC 27709
US
919 636 4530
About Fennec Pharmaceuticals Inc.
Fennec Pharmaceuticals Inc. operates as a biopharmaceutical firm. Its leading investigational drug in clinical development is PEDMARK, a specialized formulation of sodium thiosulfate. This treatment is designed to shield young cancer patients from hearing damage (ototoxicity) that can be induced by platinum-based chemotherapy. The company, which was founded in 1996, previously operated under the name Adherex Technologies Inc. before officially rebranding as Fennec Pharmaceuticals Inc. in September 2014. Its corporate headquarters are situated in Research Triangle Park, North Carolina.
Latest News
Can Adherex Technologies (FENC) Climb 26.53% to Reach the Level Wall Street Analysts Expect?
Adherex Technologies Inc. (FENC) Beats Q2 Earnings and Revenue Estimates
Fennec Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update
Septerna, Inc. (SEPN) Reports Q2 Loss, Beats Revenue Estimates
Is the Options Market Predicting a Spike in Adherex Technologies Stock?
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Raykov Rosty | S-Sale | 10,000 | $12.11 | 2026-09-01 |
| Raykov Rosty | A-Award | 2,778 | — | 2026-08-31 |
| Sayad Pierre Sargis | A-Award | 168 | — | 2026-08-31 |
| Sayad Pierre Sargis | S-Sale | 12,000 | $12.18 | 2026-08-31 |
| Evans Terry L | A-Award | 168 | — | 2026-08-31 |